• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Acute generalized exanthematous pustulosis to a novel oral anticoagulant (apixaban)
Non-vitamin K antagonist oral anticoagulants or novel oral anticoagulants (NOACs) are increasingly used in the prevention of stroke in atrial fibrillation and in the prevention and treatment of venous thromboembolism (VTE). NOACs include direct thrombin inhibitor dabigatran and factor Xa inhibitors apixaban, edoxaban and rivaroxaban. Severe cutaneous adverse reactions are rare with definite cases of drug reaction with eosinophilia and systemic symptoms (DRESS) attributed to both rivaroxaban and apixaban1,2.
Source: Annals of Allergy, Asthma and Immunology - August 2, 2021 Category: Allergy & Immunology Authors: Suran L Fernando, Jamma Li, Chris Toon, Chris Weir Source Type: research

Delayed hypersensitivity reactions to edoxaban
Edoxaban is the fourth approved Direct Oral AntiCoagulant (DOAC) that has been introduced into the European market (2015), after dabigatran (2008), rivaroxaban (2008) and apixaban (2011). Dabigatran is the only direct thrombin inhibitor, whereas apixaban, edoxaban, and rivaroxaban are factor-Xa inhibitors. In a few years DOACs' use steadily increased in clinical practice for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) [1], as well as for treatment and prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE)[2].
Source: Annals of Allergy, Asthma and Immunology - August 27, 2020 Category: Allergy & Immunology Authors: Laura Franceschini, Giulia Carli, Giancarlo Landini, Daniela Matarrese, Alessandro Farsi Tags: Letters Source Type: research